The anti-MUC1 chimeric antigen receptor (CAR) Jurkat cell line is a stable cell line derived from anti-MUC1 CAR lentivirus transduction. This transduced CAR lentiviral vector was constructed to express scFv of an anti-MUC1 antibody linked to the CD28 and CD3ζ signaling domains. And this recombinant cell product can be used to target human MUC1 and treat Colorectal cancer.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell as a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE